Nuevolution Appoints Henrik Simonsen, former Director of Life Science Corporate Finance at SEB, as its Chief Financial Officer

Copenhagen, Denmark, September 16th, 2015 – Nuevolution A/S, a leading small molecule drug discovery company, today announced that Henrik Simonsen has joined the company in the position as Chief Financial Officer. In his role, Mr. Simonsen will lead Nuevolution’s financial strategy including corporate finance and investor relations. As member of Nuevolution’s Executive Management, he will play a key part in the strategy planning going forward. His most recent position was at SEB, where he was Sector Responsible for the Life Science arm of the Corporate Finance practice.

With Henrik Simonsen, Nuevolution appoints a seasoned professional, who has over 20 years of experience as an equity analysts covering Nordic, European and US life science companies as well as a number of years of corporate finance experience including several biotech IPO’s in Scandinavia.

“The appointment of Henrik Simonsen, to take charge of Nuevolution’s financial strategy and investor relations, represents an important step for Nuevolution in realization of our ambitious strategy of establishing a broad portfolio of clinical and pre-clinical programs within oncology, immunology and immuno-oncology.” said Alex Gouliaev, CEO of Nuevolution A/S and continued “Our programs addresses diseases with significant unmet need, and should therefore be developed as rapidly as possible. With Henrik’s strong corporate finance experience and investor network, we are confident that he will play a key role in helping secure future financing needed in realization of these important goals.”

“I am thrilled to be joining Nuevolution, which has developed the state-of-the art drug discovery platform, Chemetics, collaborates with leading drug companies and is building a promising pipeline in oncology, immuno-oncology and inflammation”, says Henrik Simonsen.

Most recently, Henrik served as Director and Sector Responsible for Life Science within Corporate Finance at SEB, where he was leading a number of Initial Public Offerings, venture capital raising initiatives as well as acting as an advisor to the executive management of several pharmaceutical and biotech companies. Prior to SEB Corporate Finance, Henrik was Senior Equity Analyst at SEB and at Nordea Securities. Henrik obtained his Master of Science in Economics degree from the University of Copenhagen.

For further enquiries about Nuevolution please contact:
Nuevolution A/S
Alex Haahr Gouliaev, CEO
Phone: +45 7020 0987

About Nuevolution
Nuevolution is a leading small molecule drug discovery biotech company founded in 2001, and based in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

The company has developed its proprietary drug discovery platform Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery platform for both identification and optimization of hit to candidate compounds. Chemetics® enables rapid oligonucleotide e.g. DNA encoded synthesis of up to billions of chemically diverse drug-like small molecule compounds, and the efficient screening and optimization of these, facilitating the identification of potent drug leads at unprecedented speed and scale.

Nuevolution has also entered into agreements with Merck & Co. (MSD), Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis, Boehringer Ingelheim and Cancer Research Technology, where Lexicon Pharmaceuticals, GlaxoSmithKline and Novartis have entered into technology licensing agreements with Nuevolution. Nuevolution has also entered a scientific collaboration by and between Duke University, Howard Hughes Medical Institute, Lexicon Pharmaceuticals and Nuevolution.

Nuevolution is a privately owned company by key Scandinavian investors, including SEB Venture Capital, Sunstone Capital and Industrifonden.
Chemetics® is a registered trademark of Nuevolution.

Chemetics® is a patented technology of Nuevolution: EP1402024, EP19005829, EP2305808,
US7727713, US8932992, EP1487978, EP2186897, US7413854, US8808984, EP1539980, EP1756277,
US13/179283, EP1608748, EP2236606, US 7915201, EP1558744, EP2348124, AU2003273792,
AU2011226815, CNZL200380104764.5, HK1082742, HK1149947, IN213390, IL167531, JP4895608,
JP5643398, ZA2005/02624, NZ538993, SG111515, US8206901, US8722583, US13/455223,
US14/099106, US7704925, EP1957644, US14/571941, US14/340123, US10/539288, US13/179283,
CA2544153, CN201210222023.8, EP10184069.2, HK11107866.3, IL207672, IN178/MUMNP/2007,
JP2010-226107, US13/455,223, US14/099106, US10/572,644, EP10192716.8, EP10192717.6,
US12/095778, CA2832672, EP11720372.9, IN9924/DELNP/2012, US13/641,588.
For further information about Nuevolution A/S, please visit our website: www.nuevolution.com